[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"LanZhou University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":319},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,75,115,149,178,202,225,244,271,293],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641776","probiotic-yogurt-in-patients-with-chronic-cholecystitis-100641776",false,"NCT07654985","Probiotic Yogurt in Patients With Chronic Cholecystitis","Efficacy and Safety of Pediococcus Acidilactici GR-5 in Patients With Chronic Cholecystitis: A Randomized Double-Blind Placebo-Controlled Trial","GR5-CC","Inclusion Criteria:\n\n* Male or female, aged 18 to 70 years.\n* Definitive diagnosis of chronic cholecystitis (with or without gallstones), referencing the Chinese Medical Association guidelines or relevant clinical diagnostic criteria.\n* Presence of clinical symptoms including recurrent right upper quadrant discomfort or dull pain, or accompanying dyspeptic symptoms (such as abdominal bloating, belching, or nausea), with symptoms persisting or recurring for more than 3 months prior to enrollment.\n* Imaging support: Abdominal ultrasound within 3 months prior to enrollment indicating gallbladder wall thickening (typically \\> 3 mm) or wall roughness.\n* Voluntary participation and signed written informed consent form.\n\nExclusion Criteria:\n\n* Acute exacerbation of cholecystitis, purulent or gangrenous cholecystitis, or accompanying biliary obstruction or severe cholangitis requiring emergency surgical intervention.\n* History of cholecystectomy or other major gastrointestinal surgeries (e.g., gastric bypass, bowel resection).\n* Comorbidities of other severe primary diseases or malignancies, including: severe cardiovascular, renal, or neurological diseases; severe liver diseases (e.g., cirrhosis, severe viral hepatitis); and malignancies (e.g., gallbladder cancer, gastrointestinal tumors).\n* Pregnant or lactating women, or those planning to conceive during the study period.\n* Use of the following medications or preparations within 4 weeks prior to enrollment: continuous use of antibiotics, other probiotic or prebiotic preparations; currently taking choleretic or litholytic drugs that may significantly affect bile acid metabolism (e.g., ursodeoxycholic acid).\n* Known allergy to dairy products, yogurt, or any intervention ingredients, or having severe lactose intolerance.\n* Any other conditions that, in the opinion of the investigator, make the subject unsuitable for participation in this clinical study.","ALL","18 Years","70 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background and Purpose: Chronic cholecystitis is a common disease causing gallbladder inflammation, which is closely related to imbalances in gut bacteria and bile acids. This study aims to investigate whether consuming a special functional yogurt containing the probiotic Pediococcus acidilactici GR-5 can help alleviate the symptoms of chronic cholecystitis.\n\nStudy Procedures: Researchers will recruit 50 patients with chronic cholecystitis and randomly divide them into two groups. For 30 days, one group will consume the functional GR-5 probiotic yogurt, while the other group will consume regular commercial yogurt (placebo). During the study period, researchers will use abdominal imaging to check the gallbladder, evaluate clinical symptoms, and collect blood and stool samples at baseline and after the 30-day intervention. The goal is to see if this probiotic yogurt can improve gallbladder health by regulating gut bacteria and bile acid metabolism, potentially providing a new dietary and nutritional option for patients with cholecystitis.",[28],"Chronic Cholecystitis",[30,31,32,33],"Probiotics","Pediococcus acidilactici","Gut Microbiota","Bile Acids","NOT_YET_RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":22},"2026-07-01",{"date":42,"type":22},"2026-09-01",{"name":44,"class":45},"LanZhou University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100643029","gansu-nurses-health-cohort-study-100643029","NCT07645911","Gansu Nurses' Health Cohort Study","Gansu Nurses' Health Surveillance and Improvement Action Program","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Able to communicate freely, have the ability to act, and agree to participate in this study.\n\nExclusion Criteria:\n\n1. Resigned from the hospital;\n2. Without a nursing license;\n3. Have a history of mental illness or severe cognitive impairment.",true,{"count":56,"type":22},1000,"OBSERVATIONAL","This study aims to understand the health status, work stress, and occupational exposure in the work environment among nurses in Gansu Province, China. We will collect information through questionnaires and conduct follow-up surveys every two years. The results of this study will help improve working conditions for nurses in the future and provide scientific evidence for developing health protection policies for the nursing workforce.",[60,61,62,63,64],"Nurses' Occupational Health","Mental Health","Chronic Diseases","Occupational Exposure","Reproductive Health",[66,67,68],"Nurses, Occupational Health, Questionnaire Survey","Nurse health status","Nurse Health Cohort Study","2026-06-10",{"date":35,"type":38},{"date":69,"type":22},{"date":73,"type":22},"2032-12-31",{"name":44,"class":45},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":57,"phases":4,"briefSummary":86,"conditions":87,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100617125","recurrence-after-gastric-and-intestinal-polyp-resection-100617125","NCT07314554","Recurrence After Gastric and Intestinal Polyp Resection","Recurrence Rate and Risk Factors After Endoscopic Resection of Gastric and Intestinal Polyps: A Retrospective and Prospective Cohort Study","RAGIP","Inclusion Criteria:\n\n* Age 18 years or older\n* First-time endoscopic examination (gastroscopy or colonoscopy) at the study center\n* Pathologically confirmed polyp of any type (adenomatous, hyperplastic, inflammatory, fundic gland polyp, hamartomatous, serrated lesion)\n* Complete endoscopic resection performed (including EMR, ESD, snare polypectomy, hot biopsy forceps, or argon plasma coagulation)\n* Negative resection margins or complete resection assessed by pathology\n* At least one follow-up endoscopic examination completed (for retrospective cohort) or willingness to complete follow-up (for prospective cohort)\n* Complete baseline clinical data available\n\nExclusion Criteria:\n\n* Hereditary polyposis syndromes (familial adenomatous polyposis, Lynch syndrome, Peutz-Jeghers syndrome, juvenile polyposis syndrome)\n* Inflammatory bowel disease (ulcerative colitis or Crohn's disease)\n* Previous history of gastric or colorectal cancer\n* Cancer detected at initial resection (stage T1b or higher)\n* Non-polyp pathology (e.g., submucosal tumors, normal mucosa)\n* Incomplete resection with positive margins that were not re-treated\n* Lost to follow-up with no available surveillance data (for retrospective cohort)\n* Pregnancy at time of enrollment\n* Inability or unwillingness to provide informed consent (for prospective cohort)",{"count":84,"type":22},2000,"3 Years","This is a retrospective and prospective cohort study designed to evaluate the recurrence rate and identify risk factors after endoscopic resection of gastric and intestinal polyps.\n\nBACKGROUND: Gastric and intestinal polyps are common digestive diseases with potential for malignant transformation. Although endoscopic resection is the standard treatment, recurrence rates range from 10-50%, and the mechanisms and risk factors remain unclear.\n\nOBJECTIVES:\n\nPrimary: To assess short-term (1-year) and long-term (3-year) recurrence rates after endoscopic polyp resection Secondary: To identify independent risk factors and develop a recurrence risk prediction model\n\nDESIGN: Mixed retrospective-prospective cohort study\n\n* Retrospective cohort: Patients who underwent polyp resection from 2021-2022, with follow-up data through 2024\n* Prospective cohort: Patients enrolled from 2024-2025, with standardized follow-up through 2028\n\nSETTING: Single tertiary referral center with \\>10,000 endoscopic polyp resections performed since 2021\n\nPARTICIPANTS: Approximately 1,600-1,800 adult patients (≥18 years) who underwent complete endoscopic resection of gastric or intestinal polyps\n\nFOLLOW-UP:\n\n* Short-term: 1 year post-resection (±2 months)\n* Long-term: 3 years post-resection (±3 months)\n\nMAIN OUTCOME: Recurrence rate defined as new polyp detection at original or different sites during endoscopic surveillance\n\nPOTENTIAL RISK FACTORS: Patient demographics, polyp characteristics (size, number, location, pathology), resection method, Helicobacter pylori status, lifestyle factors, and medication use\n\nEXPECTED IMPACT: Results will inform personalized surveillance strategies and optimize resource allocation for post-polypectomy follow-up.",[88,89,90,91,92,93,94],"Gastric Polyps","Intestinal Polyps","Colon Polyps","Colorectal Polyps","Adenomatous Polyps","Gastric Adenoma and Early Gastric Cancer","Colorectal Adenoma",[96,97,98,99,100,101,102,103,104,105,106],"Polyp recurrence","Endoscopic resection","Polypectomy","Endoscopic mucosal resection","Endoscopic submucosal dissection","Risk factors","Surveillance","Follow-up","Adenoma","Gastric polyp","Colorectal polyp","2026-06-07",{"date":109,"type":38},"2026-06-09",{"date":111,"type":22},"2026-07-26",{"date":113,"type":22},"2029-02-25",{"name":44,"class":45},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":127,"conditions":128,"keywords":134,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":46},"100616957","phase-4-esomeprazole-plus-sucralfate-for-post-esd-ulcer-healing-100616957","NCT07312370","Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","Intravenous Esomeprazole Combined With Sucralfate Suspension for Ulcer Healing and Complication Prevention After Gastric Endoscopic Submucosal Dissection: A Prospective, Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years, male or female\n2. Diagnosed with early gastric cancer or high-grade intraepithelial neoplasia planned for gastric ESD\n3. Lesion location: Gastric corpus, antrum, or angle (cardiac lesions may be included but will require subgroup analysis)\n4. Successful en bloc resection achieved by ESD\n5. Post-ESD artificial ulcer diameter ≥2 cm\n6. Complete coagulation of all visible vessels during ESD procedure\n7. ECOG performance status 0-1\n8. Able to comply with follow-up visits and endoscopic examinations\n9. Voluntary participation with written informed consent\n\nExclusion Criteria:\n\n1. Previous gastric surgery history\n2. Active peptic ulcer disease (confirmed by pre-ESD endoscopy) within 1 month\n3. Recent upper gastrointestinal bleeding (within 1 month, excluding tumor-related bleeding)\n4. Severe heart, liver, or kidney dysfunction (Child-Pugh class C, NYHA class III-IV, or CKD stage 4-5)\n5. Coagulation disorders (INR \\>1.5 or platelet count \\\u003C50×10⁹\u002FL)\n6. Uncontrolled diabetes (HbA1c \\>9%)\n7. Known allergy or hypersensitivity to PPIs or sucralfate\n8. Use of PPIs, H2 receptor antagonists, or mucosal protective agents within 2 weeks prior to ESD\n9. Long-term anticoagulant therapy that cannot be discontinued (e.g., warfarin, direct oral anticoagulants)\n10. Long-term NSAIDs or aspirin (\\>100mg\u002Fday) that cannot be discontinued\n11. Unsuccessful complete (en bloc) resection (piecemeal resection)\n12. Intraoperative perforation\n13. Uncontrolled active bleeding during ESD\n14. Pregnancy or lactation\n15. Women of childbearing potential not using adequate contraception\n16. Concurrent participation in another clinical trial\n17. Any condition that, in the investigator's opinion, makes the patient unsuitable for study participation","80 Years",{"count":124,"type":22},120,[126],"PHASE4","Endoscopic submucosal dissection (ESD) is an established treatment for early gastric cancer and precancerous lesions. Post-ESD artificial ulcers may lead to complications including delayed bleeding (3-15%) and prolonged healing. Current guidelines recommend high-dose proton pump inhibitors (PPIs), but evidence for additional mucosal protective agents remains limited.\n\nThis study aims to evaluate whether combining sucralfate suspension with standard intravenous esomeprazole therapy improves ulcer healing and reduces complications after gastric ESD compared to esomeprazole alone.\n\nThis is a prospective, randomized, controlled, outcome-assessor-blinded trial. A total of 120 patients undergoing gastric ESD will be randomly assigned 1:1 to receive either:\n\n* Intervention group: Intravenous esomeprazole 40mg twice daily (3 days) followed by oral esomeprazole 40mg once daily PLUS sucralfate suspension 1g twice daily for 8 weeks\n* Control group: Intravenous esomeprazole 40mg twice daily (3 days) followed by oral esomeprazole 40mg once daily for 8 weeks The primary outcome is ulcer reduction rate at 4 weeks post-ESD, assessed by endoscopy. Secondary outcomes include complete ulcer healing rate at 8 weeks, delayed bleeding rate, symptom scores, and safety parameters.\n\nThis study will provide high-quality evidence regarding the role of sucralfate as an adjunctive therapy for post-ESD ulcer management and may inform future clinical guidelines.",[129,130,131,132,133],"Early Gastric Cancer","Gastric Dysplasia","Gastric Neoplasms","Peptic Ulcer With Haemorrhage","Gastric Ulcer",[135,136,137,138,139,140],"Endoscopic Submucosal Dissection","Gastric Cancer","Ulcer Healing","Proton Pump Inhibitor","Post-ESD Ulcer","Early Gastric Neoplasm","2026-03-19",{"date":143,"type":38},"2026-03-23",{"date":145,"type":22},"2026-04-20",{"date":147,"type":22},"2026-12-30",{"name":44,"class":45},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":165,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":46},"100613229","enhanced-ward-rounds-for-bowel-preparation-quality-in-hospitalized-patients-undergoing-colonoscopy-100613229","NCT07263867","Enhanced Ward Rounds for Bowel Preparation Quality in Hospitalized Patients Undergoing Colonoscopy","Effect of Increased Frequency of Resident Ward Rounds on Bowel Preparation Quality in Hospitalized Patients Undergoing Therapeutic Colonoscopy: A Cluster-Randomized Crossover Trial","ENHANCE-BP","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalized patients (inpatients)\n3. Scheduled for therapeutic colonoscopy (polypectomy, endoscopic mucosal resection \\[EMR\\], endoscopic submucosal dissection \\[ESD\\], or biopsy for diagnosis)\n4. Time from admission to scheduled colonoscopy ≥48 hours (allowing adequate preparation time)\n5. Patient or legal representative able to provide written informed consent\n6. Able to understand and follow bowel preparation instructions (with assistance from caregivers if needed)\n\nExclusion Criteria:\n\n1. Emergency gastrointestinal conditions: bowel obstruction, acute lower gastrointestinal bleeding requiring urgent intervention, suspected or confirmed perforation\n2. Emergency or same-day colonoscopy (scheduled \\\u003C24 hours after admission)\n3. History of total colectomy or current colostomy\u002Fileostomy\n4. Severe cognitive impairment (Mini-Cog score 0-1 or MMSE \\\u003C18) without available caregiver\n5. Severe cardiopulmonary disease: New York Heart Association (NYHA) Class IV heart failure, chronic kidney disease (CKD) stage 4-5 (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m²) unable to tolerate PEG-based preparation\n6. Known or suspected pregnancy, currently breastfeeding\n7. Previous severe allergic reaction to PEG or bowel preparation agents\n8. Current participation in another interventional clinical trial\n9. Unable to provide informed consent and no legal representative available\n10. Patient or legal representative declines participation",{"count":158,"type":22},300,[25],"Adequate bowel preparation is critical for successful colonoscopy, yet inadequate preparation remains a significant clinical challenge, occurring in 20-30% of procedures. In hospitalized patients undergoing therapeutic colonoscopy, suboptimal preparation leads to increased costs, prolonged hospital stay, and potential procedure cancellation or rescheduling. Current standard care involves resident ward rounds twice daily.\n\nThis cluster-randomized crossover trial aims to evaluate whether increasing the frequency of structured resident ward rounds from 2 to 4 times per day can improve bowel preparation quality in hospitalized patients scheduled for therapeutic colonoscopy. The enhanced ward round intervention includes standardized checklist review, medication verification, dietary compliance confirmation, adverse event screening, and timely intervention when needed.\n\nThree hospital wards will be randomly assigned to different sequences of intervention and control periods using a crossover design with washout periods. The primary outcome is adequate bowel preparation quality assessed by Boston Bowel Preparation Scale (BBPS ≥6 with each segment ≥2), evaluated by blinded endoscopists. Secondary outcomes include procedure quality metrics (cecal intubation rate, examination duration), safety endpoints (electrolyte disturbances, aspiration events), health economics measures (length of stay, total costs), and healthcare worker burden (nursing workload, night-time call frequency).\n\nSubgroup analyses will examine intervention effects across age groups, cognitive function levels, prior colonoscopy experience, and comorbidity burden to identify populations most likely to benefit from enhanced monitoring.\n\nThis pragmatic trial addresses a clinically relevant question using a real-world implementation strategy designed to minimize workflow disruption. Results will inform evidence-based policies regarding optimal ward round frequency for colonoscopy preparation in hospital settings.",[162,163,164],"Colonoscopy","Bowel Preparation","Quality of Healthcare",[166,167,168,169,170],"Bowel preparation","Ward rounds","Colonoscopy quality","Cluster randomized trial","Boston Bowel Preparation Scale","2026-03-04",{"date":173,"type":38},"2026-03-06",{"date":175,"type":22},"2026-03-28",{"date":147,"type":22},{"name":44,"class":45},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":46},"100614998","enhanced-ward-rounds-and-communication-for-pre-procedural-anxiety-in-gi-endoscopy-patients-100614998","NCT07286877","Enhanced Ward Rounds and Communication for Pre-procedural Anxiety in GI Endoscopy Patients","Enhanced Ward-Round Frequency With Standardized Communication for Pre-procedural Anxiety in Hospitalized Patients Undergoing Therapeutic Gastrointestinal Endoscopy","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Inpatients scheduled for therapeutic gastrointestinal endoscopy (e.g., ESD\u002FEMR, therapeutic colonoscopy).\n3. Able to provide informed consent and complete required assessments.\n\nExclusion Criteria:\n\nEmergency\u002Fimmediate endoscopy required.\n\n1. Severe cognitive impairment or psychotic disorder affecting assessments. Isolation\u002Fsingle room preventing protocol implementation.\n2. Unable to complete the primary pre-procedure assessment within the 2-4 hour window.",{"count":56,"type":22},[25],"This study tests a new way to help reduce anxiety in hospitalized patients waiting for therapeutic gastrointestinal (GI) endoscopy procedures, like EMR or ESD. Anxiety before these procedures is common and can make preparation harder, increase medication needs, and affect recovery.\n\nWe compare standard ward checks (twice a day) to enhanced checks (four times a day) with structured talks and simple relaxation exercises. The goal is to see if the enhanced approach lowers anxiety levels, measured by a standard scale called the Hamilton Anxiety Rating Scale (HAM-A), from baseline to 24 hours before the procedure.\n\nWho can join? Adults (18+) scheduled for inpatient GI endoscopy with at least 2 days hospital stay and mild anxiety. Exclusions include emergencies or severe mental health issues.\n\nThe study is done in hospital wards, with groups assigned by ward periods to keep it real-world. Benefits may include less anxiety and better experience; risks are low as it's just more supportive talks. Participation is voluntary with informed consent. Results could improve hospital care routines.",[189,190,191,192,193],"Anxiety","Depression Disorders","Sleep Wake Disorders","Gastrointestinal Diseases","Preoperative Anxiety","2025-12-13",{"date":196,"type":38},"2025-12-16",{"date":198,"type":22},"2026-01-15",{"date":200,"type":22},"2027-02-20",{"name":44,"class":45},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":46},"100599543","study-of-the-preventive-effects-and-mechanisms-of-yeast--glucan-on-upper-respiratory-tract-infections-100599543","NCT07085858","Study of the Preventive Effects and Mechanisms of Yeast β-Glucan on Upper Respiratory Tract Infections","Inclusion Criteria:\n\n1. Aged between 18 and 35 years;\n2. Meeting the symptom criteria for persistent allergic rhinitis (AR) as defined in the Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition): (1) Symptoms: Two or more of the following-paroxysmal sneezing, watery rhinorrhea, nasal itching, and nasal congestion-lasting continuously or cumulatively for at least 1 hour per day; ocular symptoms such as tearing, itching, and redness may also be present; (2) Persistent AR: Symptoms occur on ≥4 days per week and persist for ≥4 consecutive weeks;\n3. No use of probiotics, prebiotics, synbiotics, antihistamines, corticosteroids, or immunosuppressants within 1 month prior to screening;\n4. Willing and able to maintain usual physical activity levels and dietary patterns during the study;\n5. Able and willing to sign the informed consent form voluntarily.\n\nExclusion Criteria:\n\n1. Use of antibiotics, osmotic laxatives (e.g., magnesium sulfate, lactulose), anthraquinone-containing agents (e.g., rhubarb, aloe, senna), or gastrointestinal motility-promoting drugs (e.g., metoclopramide, domperidone, cisapride) within 1 month prior to screening;\n2. Diagnosed with non-allergic rhinitis (e.g., vasomotor rhinitis, infectious rhinitis, hormonal rhinitis, drug-induced rhinitis), or with nasal polyps, severe nasal septum deviation, cerebrospinal fluid rhinorrhea, or aspirin-exacerbated respiratory disease (AERD);\n3. Patients with uncontrolled allergic comorbidities, including sinusitis, otitis media, allergic asthma, or atopic dermatitis;\n4. History of serious gastrointestinal diseases (e.g., severe diarrhea, inflammatory bowel disease), or gastrointestinal endoscopy within the past month;\n5. Diagnosed with congenital genetic disorders, primary immunodeficiency diseases, severe systemic illnesses, or malignancies;\n6. Influenza vaccination within the past 6 months;\n7. Pregnant or lactating women, or women with plans to conceive during the study period.","35 Years",{"count":210,"type":22},96,[25],"This study is designed as a randomized, double-blind, placebo-controlled human intervention trial targeting a population of university students with persistent allergic rhinitis (AR) symptoms. The primary objective is to evaluate the preventive effect and underlying mechanisms of yeast β-glucan on upper respiratory tract infections (URTIs), providing scientific evidence for the prophylactic use of prebiotics in high-risk populations.\n\nAll participants will be stratified by sex and body mass index (BMI), and then randomly assigned to either the yeast β-glucan group or the control group. During the 15-week study period-including a 1-week run-in phase, a 12-week intervention phase, and a 2-week follow-up phase-participants in the intervention group will take two yeast β-glucan capsules daily after meals, while the control group will take two placebo capsules with identical appearance, taste, and packaging.\n\nParticipants will be monitored daily for the occurrence of URTIs. In the event of an infection, the Wisconsin Upper Respiratory Symptom Survey (WURSS-24) will be used to assess symptom severity and duration. Medication use, including dosage, frequency, and timing, will also be recorded. Weekly follow-ups will assess changes in Total Nasal Symptom Score (TNSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and adverse events. In addition, participants will undergo comprehensive follow-up assessments at Week 0 and Week 12, including TNSS and RQLQ questionnaires, a 3-day dietary intake survey, anthropometric measurements (e.g., height, weight, body fat percentage), and biological sample collection (blood, urine, and stool samples).",[214],"Upper Respiratory Tract Infections",[216,217],"Upper respiratory tract infections","Yeast β-glucan","2025-07-18",{"date":220,"type":38},"2025-07-25",{"date":220,"type":22},{"date":223,"type":22},"2026-12-31",{"name":44,"class":45},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":243,"locationsCount":46},"100599073","study-of-the-effects-and-mechanisms-of-yeast-postbiotics-on-persistent-allergic-rhinitis-symptoms-100599073","NCT07079748","Study of the Effects and Mechanisms of Yeast Postbiotics on Persistent Allergic Rhinitis Symptoms","Inclusion Criteria:\n\n1. Aged between 18 and 35 years;\n2. Meeting the symptom criteria for persistent allergic rhinitis (AR) as defined in the Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition): (1) Symptoms: Two or more of the following-paroxysmal sneezing, watery rhinorrhea, nasal itching, and nasal congestion-lasting continuously or cumulatively for at least 1 hour per day; ocular symptoms such as tearing, itching, and redness may also be present; (2) Persistent AR: Symptoms occur on ≥4 days per week and persist for ≥4 consecutive weeks;\n3. No use of probiotics, prebiotics, synbiotics, antihistamines, corticosteroids, or immunosuppressants within 1 month prior to screening;\n4. Willing and able to maintain usual physical activity levels and dietary patterns during the study;\n5. Able and willing to sign the informed consent form voluntarily.\n\nExclusion Criteria:\n\n1. Use of antibiotics, osmotic laxatives (e.g., magnesium sulfate, lactulose), anthraquinone-containing agents (e.g., rhubarb, aloe, senna), or gastrointestinal motility-promoting drugs (e.g., metoclopramide, domperidone, cisapride) within 1 month prior to screening;\n2. Diagnosed with non-allergic rhinitis (e.g., vasomotor rhinitis, infectious rhinitis, hormonal rhinitis, drug-induced rhinitis), or with nasal polyps, severe nasal septum deviation, cerebrospinal fluid rhinorrhea, or aspirin-exacerbated respiratory disease (AERD);\n3. Patients with uncontrolled allergic comorbidities, including sinusitis, otitis media, allergic asthma, or atopic dermatitis;\n4. History of serious gastrointestinal diseases (e.g., severe diarrhea, inflammatory bowel disease), or gastrointestinal endoscopy within the past month;\n5. Diagnosed with congenital genetic disorders, primary immunodeficiency diseases, severe systemic illnesses, or malignancies;\n6. Pregnant or lactating women, or women with plans to conceive during the study period.",{"count":232,"type":22},80,[25],"This study is designed as a randomized, double-blind, placebo-controlled human intervention trial among university students with persistent allergic rhinitis (AR) symptoms. The aim is to evaluate the effectiveness of yeast postbiotics in alleviating persistent AR symptoms and to explore the potential mechanisms by which yeast postbiotics modulate the gut microbiota to improve AR-related outcomes. A stratified randomization method will be applied to assign participants into the yeast postbiotic group and the placebo group. Stratification will be based on(1) Sex (male\u002Ffemale), and (2) Physician-diagnosed AR status (yes\u002Fno, based on self-reported clinical history), ensuring comparability between the two groups. During the intervention period, participants in the yeast postbiotic group will take two capsules of yeast postbiotic supplements daily after meals, while the placebo group will take two placebo capsules, identical in appearance and composition except without the active ingredients. The total study duration is 15 weeks, including a 1-week run-in period, 12-week intervention, and 2-week follow-up after the intervention.\n\nAll participants will be asked to complete a daily nasal symptom score (TNSS) and report any adverse events. At week 0, week 4, and week 12, follow-up assessments will be conducted, including: symptom and quality-of-life questionnaires (e.g., VAS, RQLQ), dietary intake surveys, anthropometric measurements (height, weight, body fat percentage), and biological sample collection (including blood, urine, saliva, and feces). Additionally, saliva samples will be collected specifically at week 2 of the intervention to assess mucosal immune markers.",[236],"Allergic Rhinitis",[236,238],"Yeast Postbiotics",{"date":240,"type":38},"2025-07-23",{"date":220,"type":22},{"date":223,"type":22},{"name":44,"class":45},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":46},"100577169","evaluating-the-safety-and-efficacy-of-drug-coated-autoperfusion-balloons-versus-conventional-drug-coated-balloons-guided-by-ivus-oct-multimodal-imaging-for-treating-acute-myocardial-infarction-opera-ami-study-100577169","NCT06794801","Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study","An Open-Label, Prospective, Single-Center, Randomized Controlled Trial Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study","Inclusion Criteria:\n\n1. Acute ST-Elevation Myocardial Infarction Meeting PPCI Criteria: 1) Chest pain lasting more than 20 minutes, with ST-segment elevation of at least 1 mm in two or more adjacent leads, new left bundle branch block, or evidence of posterior wall myocardial infarction; 2) Onset of symptoms within 12 hours.\n2. Patients Who Have Received Thrombolytic Therapy Within 6 Hours of Symptom Onset and Are Eligible for Rescue PCI Within 24 Hours;\n3. Infarct-Related Artery Selection Imaging and Pre-Treatment Criteria Meeting PPCI Standards: 1) De novo lesions. 2) Reference vessel diameter between 2.5 mm and 4 mm. 3) Successful pre-treatment of target lesions: post-pre-treatment residual stenosis of the culprit vessel ≤ 30%, with no type C dissections (or intravascular imaging indicating significant residual plaque burden at the site of dissection, with transverse expansion \\> 60°, longitudinal expansion \\> 2 mm, dissection involving the media or adventitia, and located at the distal end of the stent), no hematoma, and no significant thrombus (TIMI thrombus burden grade ≤ 2);\n4. Sufficient compliance with the study protocol, agreement to undertake follow-up, and coronary angiography at 9 months;\n5. Voluntary Participation in This Study, Including Signing a Written Informed Consent with Understanding of All Risks and Benefits Described in the Informed Consent Document.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years and \\> 75 years;\n2. History of prior myocardial infarction;\n3. Allergy to contrast agent\u002Finability to tolerate contrast;\n4. Known contraindications \u002F inability to tolerate bivalirudin, fondaparinux, heparin, aspirin, clopidogrel, and\u002For ticagrelor;\n5. Complex coronary lesions: left main lesions, lesions at the ostia of the left anterior descending or circumflex arteries, lesion length \\> 30 mm, severe calcification, severe tortuosity or angulation, bifurcation lesions requiring the implantation of more than two drug-coated balloons (DCBs) or drug-eluting stents;\n6. In-stent restenosis or in-stent thrombus lesions;\n7. Planned simultaneous intervention on non-target lesions;\n8. Active bleeding or recent history of bleeding;\n9. Uncertain neurological outcomes, such as resuscitation;\n10. Intubation \u002F ventilation;\n11. Cardiogenic shock prior to randomization;\n12. Known intracranial disease (tumors, aneurysms, arteriovenous malformations, hemorrhagic CVA, ischemic CVA\u002FTIA within the last 6 months, including permanent neurological deficits from ischemic cerebrovascular disease) ;\n13. Refusal of blood transfusion;\n14. Planned major surgery within 6 weeks;\n15. Stent implantation \\\u003C 1 month prior to enrollment;\n16. Life expectancy of less than 12 months;\n17. Participation in another clinical trial that interferes with this study.","75 Years",{"count":253,"type":22},134,[25],"Trial Goals:\n\n1. Evaluation of Mid- to Long-Term Safety and Effectiveness of Drug-Coated Autoperfusion Balloon Dilatation Catheter (DCAB) versus Conventional Drug coated balloon (DCB) in Patients with ST Segment Elevation Myocardial Infarction (STEMI).\n2. Evaluation of Hybrid IVUS-OCT System for Intraoperative Evaluation of DCAB or Conventional DCB Treatment Safety and Effectiveness for De Novo Lesions During Emergency Percutaneous Coronary Intervention (PCI) in Patients with STEMI.\n\nThe primary outcome is late lumen loss (LLL) assessed at 9 months following emergency PCI, measured using quantitative coronary angiography (QCA).",[257],"ST Segment Elevation Myocardial Infarction (STEMI)",[259,260,261,262],"Drug Coated Autoperfusion Balloon Dilatation Catheter","Percutaneous Coronary Intervention","VUS-OCT Multimodal Imaging","De novo lesion","2025-01-22",{"date":265,"type":38},"2025-01-27",{"date":267,"type":22},"2025-01",{"date":269,"type":22},"2030-12",{"name":44,"class":45},{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100552346","neural-circuit-mechanism-of-inflammatory-bowel-disease-combined-with-depression-100552346","NCT06471894","Neural Circuit Mechanism of Inflammatory Bowel Disease Combined With Depression","Study on the Neural Circuit Mechanism of Regulating GABA by Gut Microbiota in Inflammatory Bowel Disease Combined With Depression","NCMOIBDCWD","Inclusion Criteria:\n\naged 18-65 years right-handed active disease (CDAI score ≥150, Mayo score \\>2).\n\nExclusion Criteria:\n\nprevious brain surgery those with severe and unstable physical diseases those with contraindications for MRI who cannot tolerate long-duration MRI examinations.","65 Years",{"count":281,"type":22},100,"The goal of this observational study is to understand the effects of gut microbiota dysbiosis treatment in patients with inflammatory bowel disease (IBD) combined with depression. The main question it aims to answer is:\n\nDoes fecal microbiota transplantation (FMT) improve depression symptoms in IBD patients by altering GABA levels in the medial prefrontal cortex?\n\nParticipants already undergoing fecal microbiota transplantation (FMT) as part of their regular medical care for IBD and comorbid depression will undergo regular assessments of GABA levels, gut microbiota, and depression symptoms for the duration of the study.",[284],"Inflammatory Bowel Diseases","2024-06-23",{"date":287,"type":38},"2024-06-25",{"date":289,"type":22},"2024-07-01",{"date":291,"type":22},"2027-12-01",{"name":44,"class":45},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":302,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":46},"100485056","phase-2-zanubrutinib-in-maintenance-therapy-of-dlbcl-patients-with-initial-remission-100485056","NCT05596097","Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission","Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission","Inclusion Criteria:\n\n1. Patients with DLBCL who are diagnosed according to the 2021 NCCN Guidelines for B-cell Lymphoma, aged ≥18 years;\n2. Don't received treatment;\n3. Measurable lesions: at least 1 lymph node lesion \\> 1.5 cm in longest dimension, or at least 1 extranodal lesion \\> 1.0 cm in longest dimension, and at least 2 measurable lesions accurately measured vertical diameter;\n4. Clinical stage II (not suitable for local radiotherapy), III, IV (Ann Arbor stage); Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;\n5. Intermediate-high-risk \u002Fhigh-risk group: International Prognostic Index (IPI) score 3-5, aa-IPI score 2-3 or NCCN-IPI score ≥4;\n6. Expression of MYC, BCL-2 and BCL-6 (detected by immunohistochemistry, qualitative or quantitative detection), or MYD88, CD79A\u002FCD79B \\[9\\] and TP53 genetic abnormality \\[10\\];\n7. Patients with non-bone marrow invasion:\n\n   1. The absolute value of neutrophils≥1.5×109\u002FL\n   2. Platelets ≥100×109\u002FL (judged by the investigator according to the condition, the minimum can be ≥75×109\u002FL)\n   3. Hemoglobin ≥ 90g\u002FL;\n\n9\\. The level of biochemical indicators meets the following requirements:\n\n1. Renal function: endogenous creatinine clearance rate \\> 30ml\u002Fmin;\n2. Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal range (ULN); total bilirubin ≤ 2 × ULN (unless Gilbert syndrome is diagnosed);\n3. Coagulation function: international normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.5×ULN; 9. life expectancy ≥ 3 months; 10. The patient and family members agree and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Lymphoma with central nervous system invasion or mediastinal large B-cell lymphoma, diagnosis or treatment of malignant tumors other than DLBCL;\n2. Cannot tolerate zanubrutinib treatment, or have hypersensitivity reactions to any components of the study drug;\n3. Significant cardiovascular disease, including:\n\n   1. Myocardial infarction within 6 months prior to screening;\n   2. Unstable angina pectoris occurring within 3 months prior to screening;\n   3. Clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);\n   4. QTc (corrected by Fridericia formula): \\>450ms in men, \\>470ms in women, or other ECG abnormalities, including history of second-degree type II atrioventricular (AV) block or third-degree AV block;\n   5. Any grade 3 or 4 heart disease as defined by the New York Heart Association (NYHA) functional class;\n   6. Echocardiography (ECHO) showing left ventricular ejection fraction (LVEF) ≤40% (AHA, 2022);\n   7. Uncontrolled hypertension at screening, manifested as systolic blood pressure ≥180 mmHg and diastolic blood pressure ≥110 mmHg on at least two consecutive blood pressure measurements;\n4. Requires continuous treatment with strong or moderate CYP3A inhibitors\u002Finducers. Patients are not eligible if they have taken strong or moderate CYP3A inhibitors\u002Finducers within 7 days prior to the first dose of study drug (or have taken these drugs for less than 5 half-lives);\n5. Hepatitis B virus (HBV-DNA) ≥ 1x10\\^3 copies\u002FmL or HBV-DNA \\> 200 IU\u002FmL or active hepatitis C virus (HCV), or human immunodeficiency virus (HIV) Serologically positive;\n6. Obvious bleeding tendency, such as a history of stroke, intracranial hemorrhage within 6 months, or a history of surgery within 4 weeks;\n7. Serious infectious diseases at the same time;\n8. Refuse to take reliable contraceptive methods during pregnancy, lactation or appropriate age;\n9. Participate in another clinical trial of lymphoma treatment at the same time;\n10. Unsuitable for enrollment by the investigator.",{"count":301,"type":22},15,[303],"PHASE2","This trial is a single-center, single-arm, prospective clinical study to investigate the efficacy and safety of zanubrutinib maintenance therapy in patients with diffuse large B-cell lymphoma (DLBCL) in Initial remission. The patients were divided into two categories: 1) Zanubrutinib maintenance therapy was started after R-CHOP induction and consolidation therapy reached maximum efficacy; 2) Initiate zanubrutinib maintenance therapy after maximal response to induction and consolidation therapy with or without rituximab (R-chemo). Therefore, the data in this study will reflect the efficacy and safety of zanubrutinib in the maintenance treatment of DLBCL patients with initial remission, and will provide new insights into the clinical application of zanubrutinib.",[306],"Diffuse Large B-cell Lymphoma (DLBCL)",[306,308,309,310],"Maintenance Therapy","Zanubrutinib","Rituximab","2022-10-23",{"date":313,"type":38},"2022-10-27",{"date":315,"type":22},"2022-10-30",{"date":317,"type":22},"2026-07-30",{"name":44,"class":45},""]